ResMed, the #1 global producer of CPAP machines and masks to treat sleep apnea acquiresSomnoware, a U.S. leader in sleep and respiratory care diagnostics software. Financial details of the acquisition were not disclosed.
Somnoware software streamlines the processes of physicians and sleep labs for diagnosing and evaluating a patient’s sleep and respiratory care test results, ordering treatment equipment, setting up appointments, tracking therapy compliance, and electronically providing this information directly into a patient’s electronic health record.
As part of the acquisition, Somnoware will retain all staff and be integrated into ResMed’s Sleep & Respiratory Care business. Somnoware platform will remain an open platform to enable sleep labs, pulmonary function testing facilities, and physicians to view results from various testing solutions and help diagnosed patients get onto the treatment they need faster.
Researchers presented the findings of a randomized controlled trial evaluating the effects of Recipe 4 Success, a preventive intervention implemented across seven cities, villages, and
Novartis is one of the world’s leading pharmaceuticals companies. Photo: Taljat David / Shutterstock. Swiss pharmaceutical giant Novartis announced further financial details of its generics
M&A: ResMed Acquires Somnoware to Expand Sleep Management Offerings
by Fred Pennic Leave a Comment
What You Should Know:
Opinion | USPSTF Says No to Food Insecurity Screening — Now What?
Berkowitz is a primary care physician and health researcher. When I was a resident, one of my primary care patients was taken to the emergency
Teaching toddlers to cook boosts self-control and healthy eating habits, new study reveals
Researchers presented the findings of a randomized controlled trial evaluating the effects of Recipe 4 Success, a preventive intervention implemented across seven cities, villages, and
Signal: Pharma giant Novartis to spin-off generics brand – Pharmaceutical Technology
Novartis is one of the world’s leading pharmaceuticals companies. Photo: Taljat David / Shutterstock. Swiss pharmaceutical giant Novartis announced further financial details of its generics